Latest Tercica Stories
SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the appointment of John A.
Ambrx, a clinical stage biopharmaceutical company, has announced positive Phase I/II clinical trial data demonstrating that ARX201, the company's long-acting human growth hormone analogue developed in collaboration with Merck Serono, normalized insulin-like growth factor I levels while delivering an acceptable safety and tolerability profile in adults with growth hormone deficiency.
Regulatory News: Ipsen (Paris:IPN) announced today that stockholders of Tercica, Inc. (Nasdaq:TRCA) voted to approve its previously announced acquisition of Tercica at a special meeting of shareholders held on 16 October 2008 in Brisbane, California.
Tercica, Inc. (NASDAQ: TRCA) today announced the first results from the Increlex(R) Growth Forum Database (IGFD) Registry in two posters presented at the 90th annual meeting of the Endocrine Society in San Francisco.